CARB-X, led by Boston University, is accelerating global antibacterial innovation by investing in the development of new antibiotics and other life-saving products to combat the most dangerous drug-resistant bacteria. Our projects represent the world’s largest pre-clinical and early development pipeline of antibiotics and other therapeutics, diagnostics, microbiome and vaccines.
focused on new classes
“Antibiotics transformed modern medicine but overuse and inappropriate use have led to dangerous bacteria developing deadly resistance. Drug discovery must go hand-in-hand with concerted action to ensure antibiotics of last resort are reserved for patients where first-line treatments will not work. And we must ensure these treatments are available in all countries for those who need them.”
— Tim Jinks, Head of Drug Resistant Infections, Wellcome Trust
Watch this video with Tim Jinks on what Wellcome Trust is doing to address the rise of drug-resistant bacteria.